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Compreendendo as Formas Sólidas de 5E-(feniletenil)benzofuroxano com Diferente 
Atividade anti-T. cruzi in vivo 
Resumo: 5E-(feniletenil)benzofuroxano (5PhEBfx) foi descrito como um excelente candidato a fármaco 
anti-chagásico. Entretanto, sua biodisponibilidade oral foi afetada pelo processo de cristalização. Duas 
amostras exibindo variável atividade in vivo foram investigadas: um pó fino amarelo (5PhEBfx-Y) e 
agulhas laranjas (5PhEBfx-O). Difração de raios X de pó, calorimetria exploratória diferencial, 
espectroscopia vibracional, microscopia óptica e eletrônica de varredura foram aplicados para investigar 
as duas formas sólidas a fim de correlacionar as propriedades do estado sólido do composto 5PhEBfx 
com sua variável biodisponibilidade. Foi observado que o 5PhEBfx-Y tem uma melhor solubilidade e, 
consequentemente, maior biodisponibilidade quando comparado com o 5PhEBfx-O. Este resultado 
sugere que a diferença de atividade entre estes dois arranjos em estado sólido do 5E-
(feniletenil)benzofuroxano poderia estar associada a perfil de biodisponibilidade distinto e a variação de 
coloração do composto. 
Palavras-chave: Formas sólidas; 5E-(feniletenil)benzofuroxano; agentes anti-T. Cruzi; solubilidade; 
biodisponibilidade. 
Abstract 
5E-Phenylethenylbenzofuroxan (5PhEBfx) was reported as an excellent anti-Chagas drug candidate. 
However, its oral bioavailability was affected by the crystallization process. Two samples exhibiting 
variable in vivo activity was investigated: a thin yellow powder (5PhEBfx-Y) and orange needles 
(5PhEBfx-O). X-ray powder diffraction, differential scanning calorimetry, vibrational spectroscopy, 
optical and electron scanning microscopies were applied to investigate both solid forms in order to 
correlate the solid-state properties with the variable bioavailability of 5PhEBfx. It was observed that 
5PhEBfx-Y have a better solubility and consequently higher bioavailability when compared with 
5PhEBfx-O. This result suggests that the difference of activity between these two 5E-
Phenylethenylbenzofuroxanes could be associated with the solid forms, which also cause the coloration 
variation.  
Keywords: Solid forms; 5E-Phenylethenylbenzofuroxan; anti-T. cruzi agents; solubility; bioavailability. 
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1. Introduction 
 
5E-Phenylethenylbenzofuroxan (5PhEBfx, 
Figure 1) is currently in pre-clinical studies as 
anti-Chagas drug candidate.1-4 Chagas disease 
or American trypanosomiasis is an important 
health problem that affects around twenty 
million people in Central and South America. 
Around 2–3 million individuals develop the 
typical symptoms of this disease that results 
in 50,000 deaths yearly.5-7 Due to the current 
pharmacology for this illness is still 
inefficient8,9 we have been investigating 
during the last fifteen years, the 
development of new drugs.10 5PhEBfx was 
initially studied as a thin yellow powder 
(5PhEBfx-Y) during the initial development 
steps finding excellent in vitro11 and in vivo 
activities.3 
However, during the pre-clinical studies 
5PhEBfx was purified by successive 
crystallizations1,2 giving rise to an orange 
crystalline form (5PhEBfx-O) finding that its 
in vivo biological properties changed. In this 
last case, the compound, in its orange 
crystalline form, became less active in vivo 
than the previous solid form used in the 
initial studies (i.e. yellow powder material, 
5PhEBfx-Y)3 (Figure 2). These different 
findings could be the result of the increased 
solubility of 5PhEBfx-Y, and thus its 
bioavailability, and may suggest the existence 
of polymorphism. 
 
 
Figure 1. Structural formula of benzofuroxan with anti-T. cruzi activity 
 
 
Figure 2. Effects of the different studied solid forms of 5PhEBfx on parasitemia in the murine 
model of acute Chagas disease following experimental conditions of ref. (3) 
 
Briefly, 5PhEBfx-Y and 5PhEBfx-O were 
suspended in the vehicle (saline: tween 80, 
4:1) immediately prior to used, no more than 
30 min before the administration, and the 
formulation was orally administered to the 
animals using intragastric syringe, on a daily 
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basis, during 25 days beginning day five post-
infection (with the Tulahuen 2 strain of T. 
cruzi) (the experimental protocol with 
animals was approved by the Animal Ethics 
Committee of the Universidad Nacional de 
Rosario). The effect of each solid form, or 
vehicle (without treatment), was weekly 
evaluated by determining the blood 
trypomastigotes levels.12 The groups were 
represented by untreated animals (vehicle) 
and those receiving 5PhEBfx-Y (yellow 
powder form) and 5PhEBfx-O (orange 
crystalline form).3  
Solid drugs can exist in different solid-
state forms, such as crystalline, which 
comprise hydrates, solvates, salts and co-
crystal, and amorphous forms, with different 
range of physicochemical properties, such as 
morphology, density, stability, melting point 
and solubility of the product. This can also 
affect the biological activity, for example 
differences in the bioactivity, as consequence 
of the drug bioavailability.13,14 Usually, a 
pharmaceutical solid is manufactured in a 
stable crystalline form because the 
amorphous form could tend to convert to the 
crystalline form due to its thermodynamic 
potential instability. This avoid the possible 
interchangeable between the amorphous and 
crystalline form in lifetime. However, despite 
this possible disadvantage, the amorphous 
state has attracted considerable interest in 
the formulation of poorly soluble 
compounds. The higher molecular mobility of 
this material, for instance, may improve the 
solubility and dissolution rate of the 
pharmaceutical solid and, thus, facilitate the 
gastrointestinal absorption of the active 
components.15,16 
Several authors reported the effects of 
the solid-state properties of a drug on its 
biopharmaceutical properties.14,17,18 These 
effects could be originated at different levels. 
At a supramolecular level, the crystal packing 
of the drug molecules could give rise to 
different polymorphs, which could exhibit 
variable solubility. Given a crystalline form, 
the thermodynamic conditions of the 
preparation process could originate changes 
in the crystalline habit. Changes in the solid-
state properties are usually reflected in 
diverse microscopic and macroscopic 
physicochemical properties, like melting 
point, crystalline habit or color. A very well 
known example of the effect of 
polymorphism in the macroscopic properties 
is 5-methyl-2-[(2-nitrophenyl)amino]-3-
thiophenecarbonitrile, which has been 
crystallized in seven polymorphs varying 
color and crystalline habit. The system has 
been named ROY for its red, orange, and 
yellow crystal colors.20 Thus, not only the 
crystalline habit but also the sample color 
could be indicative of structural changes in 
the solid form. Combining these evidences 
with the variable bioavailability observed in 
the 5PhEBfx samples, one might propose that 
the solid-state properties are playing a 
relevant role in the oral in vivo activity of this 
drug. As a consequence, the aim of this work 
is to correlate the biopharmaceutical results 
of 5PhEBfx with its solid-state properties. 
Modified materials properties were 
investigated by solubility at two different 
conditions (aqueous solutions at stomach- 
and intestine-like pHs), melting point, optical 
and scanning electron (SEM) microscopies, 
Fourier-transform infrared and Raman 
spectroscopy, differential scanning 
calorimetry (DSC) and X-ray powder 
diffraction (XRPD). 
 
2. Experimental 
 
2.1. Chemicals 
 
Compound 5PhEBfx was obtained in our 
laboratory according to previously published 
methods.1 The samples homogeneity was 
achieved by NMR spectroscopy and 
microanalysis. All reagents and chemicals 
were of analytical grade. Other reagents 
were analytical grade and double distilled 
water was used throughout the experiment. 
For animal studies, Milli-Q water purified 
using Millipore system was used. 
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2.2. Preparation of solid forms 
 
Crystalline form of studied compound, 
5PhEBfx-O, was obtained by crystallization 
from petroleum ether:EtOAc. It was prepared 
by cooling a boiling petroleum ether:EtOAc 
(85:15, v/v) solution (near saturation) at 
room temperature. Amorphous material, 
5PhEBfx-Y, was prepared by dissolution in an 
appropriate amount of a mixture of 
petroleum ether:EtOAc (70:30, v/v) follow by 
solvent evaporation under vacuum, at room 
temperature in a rotary evaporator, and 
ground in a mortar. Both 5PhEBfx were 
obtained with purity major to 99 %. The solid 
materials were stored in closed glass vials. 
 
2.3. Analytical techniques 
 
2.3.1. Relative solubility of solid forms 
 
The relative solubility of 5PhEBfx-O and 
5PhEBfx-Y were determined in triplicate 
using a modified shake-flask method.21,22 Two 
different conditions were used, aqueous 
solutions at pH=2.0 like rat stomach 
condition and pH=5.0 like proximal small 
intestine in the fed state condition.23 The 
aqueous solution at different pHs were 
obtained with non-phosphate buffers. 
Increasing amounts of the studied solid were 
added to the corresponding buffer solution 
and incubated during 30 min. Then, the 
solutions were filtered and the compound 
amount was quantified by UV spectroscopy 
at 300 nm.  
 
2.3.2. X-ray powder diffraction 
 
The XRPD patterns were recorded on X-
ray diffractometer (PW 1729, Philips, The 
Netherlands). Samples were irradiated with 
monochromatized Cu-Ka radiation (1.542Å) 
and analyzed from 5o to 50o 2. The voltage 
and current used were 30 kV and 30 mA, 
respectively. 
2.3.3. Differential scanning calorimetry 
 
Thermograms were recorded using a 
Netzsch Phoenix 204 system (Netzsch, 
Germany). Duplicate samples of 1–3 mg were 
accurately weighed in sealed and pierced 
aluminium pans. Samples of each compound 
were heated from room temperature to 
approximately 50 oC above the melting 
temperature at a rate of 5 oC min-1 under 
nitrogen at a flow rate of 60 mL min-1. 
 
2.3.4. Vibrational spectroscopy 
 
Infrared spectra were recorded on a 
Bruker Vertex 70 Fourier transform 
spectrometer (Bruker Optik, Ettlingen, 
Germany). The spectrometer was equipped 
with a KBr beamsplitter, an MIR source and a 
RT-DLaTGS detector. Samples were measured 
over a wavelength range from 400 to 4000 
cm-1 and the final spectrum was the mean of 
128 scans. A RAM II module was employed to 
obtain the Raman spectra in the spectral 
range between 80 and 3600 cm-1 using a 
diode pumped Nd:YAG laser with an 
excitation wavelength of 1064 nm at a laser 
power of 100 mW. Each spectrum was the 
average of 512 scans. 
  
2.3.5. Microscopy 
 
The morphology of 5PhEBfx-O and 
5PhEBfx-Y were studied by optical 
microscopy and scanning electron 
microscope (SEM). The SEM was utilized to 
assess the morphological characteristics of 
the row materials and the drug–carrier 
systems using a Tescan Model XMU, VEGA II. 
The samples were fixed on aluminum stubs 
with double-sided tape, 15 nm gold coated 
sputter and examined in the microscope 
using an accelerating voltage of 30 kV, at a 
working distance of 8 mm. 
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3. Results 
 
3.1 Relative solubility of solid forms 
 
The relative solubility of the solid 
materials was assessed, using UV 
measurement, in two different conditions 
corresponding to the biological absorption-
pHs (Table 1, Figure 3). In the experimental 
conditions neither 5PhEBfx-O nor 5PhEBfx-Y 
achieved visually complete dissolution at the 
acidic pH (pH= 2). This observation was 
confirmed by the UV studies. The 5PhEBfx-Y 
showed relevant solubility-enhancement in 
the intestine-like pH (pH= 5).  
 
3.2. X-ray powder diffraction 
 
As it was previously stated, the studied 
solid forms exhibit distinctive colours as 
shown in Figure 4. In order to investigate the 
crystalline structure of the two samples of 
5PhEBfx X-ray powder diffraction (XRPD) 
measurements were performed. These 
results are presented in Figure 5 compared 
with the simulated pattern calculated from 
the crystalline structure of 5PhEBfx. X-ray 
single crystal measurements in 5PhEBfx-O 
allowed us to determine its crystalline 
structure.24 5PhEBfx-O crystallizes in an 
orthorhombic lattice belonging to the 
P212121 space group (a = 7.2368(6) Å, b = 
12.613(1) Å and c = 12.884(1) Å). The solid-
state packing of this compound is based on 
two contacted infinite one-dimensional 
chains parallel to [001] direction and they are 
related by a 21 screw axis symmetry along 
the c axis. Into each chain, the molecules are 
connected along the packing direction 
through a C–H…O weak intermolecular 
interaction, in a head-to-tail array, whereas 
each benzofuroxan is bonded to other two 
molecules from an adjacent chain through 
another weak non-classical intermolecular 
hydrogen bonding involving C–H…O, in a 
zigzag manner. 
 
Table 1. Relative solubility (S5PhEBfx-Y/S5PhEBfx-O) of the  solid forms in different conditions 
 
Condition S5PhEBfx-Y/S5PhEBfx-O 
pH=2.0 
both forms are completely insoluble 
in the assayed conditions  
pH=5.0 1.5 
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Figure 3. Example of UV-behavior of the solid materials of the 5PhEBfx-O and 5PhEBfx-Y at 
pH=5.0. 
 
 
Figure 4. Photograph of 5PhEBfx: orange needles (left, 5PhEBfx-O) and yellow powder (right, 
5PhEBfx-Y) 
 
 
 Honorato, S. B. et al. 
  
 
1186 Rev. Virtual Quim. |Vol 5|  |No. 6|  |1179-1190| 
 
10 15 20 25 30
Calculated
 
 
In
te
n
s
it
y
 (
a
rb
. 
u
n
it
s
)
2(deg)
 
 
5PhEBfx-O 
5PhEBfx-Y 
 
Figure 5. Comparison between the X-ray powder patterns simulated from the 5PhEBfx crystal 
structure (vertical bars) and experimental patterns of the 5PhEBfx-Y and 5PhEBfx-O at room 
temperature 
 
3.3. Differential scanning calorimetry 
 
The thermal stability of 5PhEBfx was 
investigated by differential scanning 
calorimetry (DSC). The thermograms of both 
forms are presented in Figure 6. A typical 
curve is characterized by a sharp 
endothermic event (onset: 144.9o
126.6 J/g) followed by a wide exothermic 
event (onset: 150o -966.9 J/g). The 
first event is related to the melting of the 
compound, which is followed by its 
decomposition (exothermic event). 
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Figure 6. DSC curves for 5PhEBfx-O and 5PhEBfx-Y 
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3.4. Vibrational spectroscopy 
 
Raman and infrared spectra of the 
investigated samples are presented in Figure 
7. As it was observed in XRPD and DSC 
measurements, no evidences of structural 
modifications were found in the vibrational 
spectra of 5PhEBfx. Due to that, just 
representative spectra of this compound are 
shown in Figure 7. The Raman spectrum of 
5PhEBfx was previously discussed,24 where 
quantum mechanical calculations were used 
to assign the most relevant vibrational 
modes. These calculations produced a very 
good agreement between the experimental 
and theoretical results and allow us to also 
apply them to interpretation of the infrared 
spectrum. 
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Figure 7. Raman and infrared spectra of 5PhEBfx. 
 
3.5. Scanning electron microscopy 
 
Figure 8 shows the SEM images recorded 
from 5PhEBfx-O and 5PhEBfx-Y samples. 
From these images, one can observe that 
both samples exhibit the same acicular 
crystalline habit. However, 5PhEBfx-O 
whereas a smaller particle size (around 
5PhEBfx-Y. 
 
4. Discussion 
 
According to the solubility studies 
performed, it could point out that both 
samples are insoluble in the simulated gastric 
pH conditions whereas it increases 
considerably in the intestine pH conditions 
(pH 5.0). Being the maximum solubility for 
5PhEBfx-Y 15 mg/mL and for 5PhEBfx-O 10 
mg/mL.  This increase in solubilization was 
attributed initially to amorphization of 
5PhEBfx. This information allows us to 
hypothesize that the studied solid forms 
would penetrate in vivo mainly in the rat 
proximal small intestine (Table I, Figure 3). 
After this supposition, we investigated 
whether these two samples have differential 
solid properties to be considered two 
different solid forms. The X-ray studies were 
performed in powder and crystalline form of 
the all the samples. The comparison between 
the experimental and simulated patterns of 
5PhEBfx-O confirms that the raw material is 
in the same crystalline structure that the 
measured single crystal. It is an expected 
result, but comparing 5PhEBfx-O and 
5PhEBfx-Y one may notice that both samples 
exhibit the same diffraction pattern. It is also 
important to point out that no evidence of an 
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amorphous phase is observed in X-ray 
powder diffraction. Thus, this experimental 
technique is not supporting the assumption 
that the variable solubility of the 5PhEBfx 
samples is associated to polymorphism. 
Moreover, by comparing the DSC 
thermograms of 5PhEBfx-O and 5PhEBfx-Y 
the same events can be identified in both 
samples. The vibrational spectral studies of 
5PhEBfx-O and 5PhEBfx-Y also indicated the 
total superposition of both samples. Based 
on the quantum mechanical calculations and 
the comparison with similar molecules the 
main features of the vibrational spectra were 
identified. Thus, the CC stretching bands of 
mono-substituted benzene are observed at 
1450, 1496, 1578, and 1595 cm-1. In the 
infrared spectrum the phenyl ring breathing 
modes are well visible at 785 cm-1 and 761 
cm-1, with contribution of the deformation 
modes δ(NO) from benzofuroxan. The C-H in-
phase bend is assigned at 1334 cm-1 and 1315 
cm-1 in the Raman spectrum. The C-H in-
plane bendings of the phenyl ring are 
observed at 1181 cm-1 and 1076 cm-1. 
Trigonal C-C-C bending mode of the phenyl 
group corresponds to the band at 1014 cm-1. 
In the infrared spectrum, the C-H out-of-
plane trigonal vibrations of phenyl ring are 
better observed at 996 cm-1 and 973 cm-1, 
whereas the C-H out-of-plane modes are at 
965, 918, and 879 cm-1. In the Raman 
spectrum of 5PhEBfx, two intense bands 
appear at 1630 cm-1 and 1621 cm-1. The 
former is assigned to CC stretching modes of 
the benzofuroxan with apparent 
contributions of C-C stretching of ethenyl and 
CN stretching of benzofuroxan. The δ(C-H) 
modes of benzofuroxan are observed at 1403 
cm-1. Bands above 3000 cm-1 are assigned to 
the phenyl C-H stretching modes. 
Several factors can modify the 
bioavailability of a drug and consequently its 
absorption. Some examples are the 
dissolution, pH in the absorption place, 
particle size, crystalline/amorphous forms of 
the drug, modifications in the chemical form 
and formulation adjuvants. In literature, 
several works emphasize the advantages of 
the use of amorphous pharmaceutical25-27. 
However, from the point of view of the 
thermodynamic stability, crystalline forms 
are still the best formulation option, due to 
the amorphous forms are instable and could 
go to crystalline ones. In this case, the 
dissolution rate of a drug, which is one of the 
most limiting properties affecting the 
bioavalability, is strongly influenced by the 
particle size. It is well known that the 
dissolution rate can be proportionally 
enhanced by increasing the surface area, 
which in turn increases with decreasing 
particle sizes.28-33 This approach is frequently 
used in the pharmaceutical industry to deal 
with poorly soluble drugs by a micronization 
process.30,34-36 Considering the variable 
solubility of the 5PhEBfx, SEM results clearly 
show that the main difference between the 
two investigated samples is the particle size. 
Even the preliminary observations have 
suggested that the samples could exhibit 
different crystalline forms, the solid-state 
characterization ruled out this hypothesis. On 
the other hand, the variable particle size is 
not only supported by the microscopy 
observations. The DSC thermograms and X-
ray powder diffraction patterns of the 
5PhEBfx-Y sample exhibits a slightly wider 
peaks which could be related to the smaller 
particle size. Thus, the increase in solubility of 
the 5PhEBfx-Y was attributed to the different 
particle size of this form comparing to 
5PhEBfx-O increasing the effective surface 
area available for solubilization. 
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 (a)      (b) 
 
Figure 8. Photomicrographs of different crystal habits from 5PhEBfx-O (a) and 5PhEBfx-Y (b) 
 
5. Conclusion 
 
In this work, the solid-state properties of 
two samples of the anti-Chagas 5PhEBfx with 
variable oral in vivo activity were compared. 
Our results suggest that the crystalline 
structure of the studied drug 5PhEBfx was 
preserved during the crystallization 
processes. X-ray powder diffraction, 
vibrational spectroscopy and differential 
scanning calorimetry have confirmed that the 
two samples, despite the color differences, 
possess the same crystalline structure. Based 
on scanning electron microscopy and the X-
ray powder diffraction we have inferred that 
the crystalline habit of the samples of 
5PhEBfx was the same, being differentiated 
only for the particle size. Our results show 
that the solubility of a drug can vary not only 
due to the polymorphism but also can be 
affected by the particle size, causing, thus, 
different in vivo activities. 
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